Metformin for newly diagnosed advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This Phase 2 trial studies whether metformin, added to standard hormone-blocking treatment, can improve outcomes for men with newly diagnosed metastatic hormone-sensitive prostate cancer. It’s meant to test benefits of targeting metabolism in addition to prostate cancer hormone therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed metastatic prostate cancer that is hormone-sensitive, confirmed by biopsy, with evidence of spread on scans (CT/MRI and/or bone scan).
- You must already be on ongoing hormone treatment (and continuous abiraterone plus prednisone).
- Your recent blood tests must meet safety targets (potassium is at least 3.5, and blood counts, liver tests, kidney function, and albumin must be above required minimums).
- You must be able to take the trial pill by swallowing whole tablets.
- You should NOT have diabetes or high sugar tests (fasting glucose, and/or A1C must be below the trial’s cutoffs), and you must not have a history of metformin use after your prostate cancer diagnosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding the diabetes drug dapagliflozin to a standard next-generation hormonal agent (like abiraterone or enzalutamide) works better than the hormonal agent alone for men with metastatic prostate cancer that is no longer responding to hormone therapy.
This early-phase study tests whether metformin can help prostate cancer patients who have higher body weight and/or early blood sugar problems. You would be screened for eligibility using your medical record, and the study looks mainly at your current health factors and medicines.
This trial tests if adding metformin, a common diabetes drug, to standard chemotherapy or immunotherapy can help treat advanced solid tumors. It may be an option for people who are already eligible for chemo or immunotherapy.
This trial tests two medications (metformin and a turmeric compound) as a maintenance therapy for men with prostate cancer whose PSA is rising slowly after prior treatment. The goal is to see if these drugs can keep the cancer from growing while you take a break from standard hormone therapy.
This Phase 2 study tests whether taking metformin after surgery and chemotherapy can reduce the risk of bone cancer coming back in people at high risk of relapse. You may be eligible if you have osteosarcoma or Ewing sarcoma that is not currently spread and you meet specific lab and health criteria.
This trial tests whether adding metformin (a diabetes drug) to standard chemotherapy (FOLFIRI) and targeted therapy can help people with metastatic colorectal cancer live longer or respond better to treatment.
Hear when a new Metastatic Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.